retatrutide phase 2 obesity nejm 2023 jastreboff Tirzepatide as Compared with Semaglutide for the Treatment of Retatrutide Results: Weight Loss Data

Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming

This section reviews current evidence from animal studies, clinical trials, case reports, and patient observations regarding GLP-1 agonists and male reproductive health

These compounded options typically cost a fraction of the retail price of their brand-name equivalents

In contrast to established GLP-1 receptor agonists such as Semaglutide (marketed as Wegovy and Ozempic) or dual-acting agents like Tirzepatide, Retatrutide is designed as a triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors